AbbVie submits migraine prevention drug to EMA for marketing authorisation

AbbVie has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for atogepant as a migraine treatment for adults who have at least four migraine days per month.

Atogepant is an oral calcitonin gene-related peptide (CGRP) inhibitor. If approved, it would be the first daily oral CGRP receptor antagonist migraine treatment for adults in Europe.